Merck Sharp & Dohme LLC — Sponsor Intelligence | 294 EU Trials

Filter these 294 trials by condition, phase, country and more.

Open in Search →

294 Registered trials

89 Recruiting

193 Completed trials

25 Countries active

169 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 117 Phase II/III: 15 Phase II: 61 Phase I/II: 33 Phase III/IV: 5 Phase I: 24 Phase I (Other): 36 Phase I (FiH): 3

Oversight events:

4 serious breaches 75 temporary halts 6 urgent safety measures 10 unexpected events 9 corrective measures across 38 trials

View oversight register →

100%

193 of 193 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer metastatic 8 Renal cell carcinoma 8 Non-small cell lung cancer 7 Non-alcoholic steatohepatitis 4 Respiratory syncytial virus infection 4 Non-small cell lung cancer stage IV 3 Pulmonary arterial hypertension 3 Rheumatoid arthritis 3 Bladder cancer 3 Hormone receptor positive HER2 negative breast cancer 3 Prostate cancer metastatic 3 Hormone receptor positive breast cancer 2

Top IMPs

PEMBROLIZUMAB 113 LENVATINIB 26 SACITUZUMAB TIRUMOTECAN 23 PEMBROLIZUMAB, VIBOSTOLIMAB 13 PEMBROLIZUMAB, FAVEZELIMAB 12 BELZUTIFAN 11 OLAPARIB 11 MK-4830 10 MRNA-4157 10 IFINATAMAB DERUXTECAN 8 PATRITUMAB DERUXTECAN 8 PEMBROLIZUMAB, QUAVONLIMAB 8

All trials — page 7

294 total

Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended

2024-510620-39-00 Phase III 13 countries BELZUTIFAN; LENVATINIB
Safety and Immunogenicity of Extended 2-dose Regimens of 9vHPV Vaccine Ended

2022-500256-37-00 Phase III 1 country HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended

2023-506839-15-00 Phase I/II 5 countries BELZUTIFAN; LENVATINIB; MK-4830; PEMBROLIZUMAB; PEMBROLIZUMAB, FAVEZELIMAB; PEMB…
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended

2023-504959-27-00 Phase III 11 countries OLAPARIB; PEMBROLIZUMAB
A clinical study of belzutifan for treatment of kidney cancer (MK-6482-013) Ended

2022-502123-21-00 Phase II 4 countries BELZUTIFAN
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… Ended

2023-503591-25-00 Phase III 12 countries DURVALUMAB; OLAPARIB; PEMBROLIZUMAB
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age Ended

2022-501974-21-00 Phase III 6 countries HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended

2023-503500-87-00 Phase III/IV 11 countries PEMBROLIZUMAB
Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera… Ended

2022-501973-37-00 Phase III 13 countries PEMBROLIZUMAB
A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended

2023-504821-38-00 Phase II 8 countries PEMBROLIZUMAB
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Phase III 10 countries PEMBROLIZUMAB
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 Phase III 8 countries PEMBROLIZUMAB
MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo… Ended

2022-500254-41-00 Phase III 9 countries PEMBROLIZUMAB
A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended

2022-501817-29-00 Phase III 13 countries PEMBROLIZUMAB
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended

2022-501966-23-00 Phase III 6 countries PEMBROLIZUMAB
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Phase III 11 countries PEMBROLIZUMAB
PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended

2022-501253-37-00 Phase II 9 countries PEMBROLIZUMAB
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage… Ended

2023-509136-25-00 Phase III 13 countries PEMBROLIZUMAB
A scientific study on a vaccine against HPV infection (human papilloma virus) (a vaccine for the prevention of cervical cancer and genit… Ended

2023-508683-30-00 Phase III 3 countries HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
Posaconazole (MK-5592) IV and oral in children (less than 2 years) with IFI Halted

2023-505613-24-00 Phase II 3 countries POSACONAZOLE
A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002) Ended

2025-524852-74-00 Phase I (Other) 1 country
A clinical study of MK-6050 in healthy people (MK-6050-001) Ended

2025-523861-58-00 Phase I 1 country
A clinical study of MK-4082 in healthy people (MK-4082-001) Ended

2025-522100-25-00 Phase I 1 country
A clinical study of MK-4646 in people with HIV (MK-4646-003) Ended

2025-521102-17-00 Phase I (Other) 1 country

Showing 145–168 of 294 trials

← All sponsors A–Z